Caitlin Edgmon
Women's Health · Athens, ALNPI 1386049856
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.7% of the total across 71 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 20.2% — the pattern of someone who eats at a lot of different presentations.
Across 71 payments — averaging $17.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$244
- Mayne Pharma Commercial LLC$231
- Astellas Pharma US Inc$153
- Pfizer$99
- Bayer$84
- Shield Therapeutics Inc$76
- plus $324 from 9 others
What the payments were for
- Food & beverage$1,11292%
- Education$1008%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 16 | $244 |
| Mayne Pharma Commercial LLC | 16 | $231 |
| Astellas Pharma US Inc | 6 | $153 |
| Pfizer | 5 | $99 |
| Bayer | 5 | $84 |
| Shield Therapeutics Inc | 4 | $76 |
| Sage Therapeutics, LLC | 3 | $64 |
| Exeltis, USA Inc. | 4 | $57 |
| Therapeuticsmd, Inc. | 3 | $51 |
| Supernus Pharmaceuticals, Inc. | 2 | $42 |
| Evofem Biosciences, Inc. | 2 | $25 |
| Mylan Pharmaceuticals Inc. | 2 | $25 |
| Organon | 1 | $22 |
| Axonics, Inc. | 1 | $22 |
| Scynexis, Inc. | 1 | $16 |
How this compares
$1,212 in reported general payments places this provider in the 70th percentile of 107 women's health providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 30 | $3,143 |
| Estradiol-Norethindrone AcetatEstradiol/Norethindrone Acet | 22 | $2,483 |
| ValacyclovirValacyclovir Hcl | 15 | $424 |
| Fluconazole | 17 | $101 |
Paid to pharmacies, not to this prescriber.
Other women's health in Athens
- Ashton TureaudBirmingham$26K
- Mary MatteiMobile$10K
- Kathryn LyleBirmingham$7K
- Tracy BrownFoley$6K
- Kimberly PeekHuntsville$6K
- Karen HammondHoover$6K
- Jessica MorrisonBirmingham$5K
- Dawna FranklinBirmingham$5K
- Mitzi ThompsonSpanish Fort$3K
- Katie FainBirmingham$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.